vs
Side-by-side financial comparison of CAMTEK LTD (CAMT) and Indivior Pharmaceuticals, Inc. (INDV). Click either name above to swap in a different company.
Indivior Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($357.0M vs $242.0M, roughly 1.5× CAMTEK LTD). Indivior Pharmaceuticals, Inc. runs the higher net margin — 28.9% vs 28.1%, a 0.7% gap on every dollar of revenue.
Camtek Ltd is a leading global developer and manufacturer of high-precision inspection and metrology systems for the semiconductor, printed circuit board, and advanced packaging industries. Its solutions support process control, defect detection, and yield optimization for clients across Asia, North America, and Europe.
Indivior is a global specialty pharmaceutical company dedicated to developing and commercializing evidence-based treatments for substance use disorders such as opioid use disorder and alcohol dependence, as well as related mental health conditions. Its primary operating markets are North America and Europe, with a portfolio of approved therapies targeting unmet medical needs for underserved patient groups.
CAMT vs INDV — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $242.0M | $357.0M |
| Net Profit | $68.0M | $103.0M |
| Gross Margin | 50.9% | 82.1% |
| Operating Margin | 26.7% | 22.7% |
| Net Margin | 28.1% | 28.9% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 390.5% |
| EPS (diluted) | — | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $357.0M | ||
| Q3 25 | — | $314.0M | ||
| Q2 25 | $242.0M | $302.0M | ||
| Q1 25 | — | $266.0M | ||
| Q3 24 | — | $307.0M | ||
| Q2 24 | $199.6M | $299.0M |
| Q4 25 | — | $103.0M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | $68.0M | $18.0M | ||
| Q1 25 | — | $47.0M | ||
| Q3 24 | — | $22.0M | ||
| Q2 24 | $52.8M | $-97.0M |
| Q4 25 | — | 82.1% | ||
| Q3 25 | — | 73.2% | ||
| Q2 25 | 50.9% | 82.8% | ||
| Q1 25 | — | 83.1% | ||
| Q3 24 | — | 78.5% | ||
| Q2 24 | 48.1% | 73.6% |
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | 26.7% | 23.8% | ||
| Q1 25 | — | 24.8% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | 23.6% | -39.5% |
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 13.4% | ||
| Q2 25 | 28.1% | 6.0% | ||
| Q1 25 | — | 17.7% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | 26.4% | -32.4% |
| Q4 25 | — | $0.79 | ||
| Q3 25 | — | $0.33 | ||
| Q2 25 | — | $0.14 | ||
| Q1 25 | — | $0.38 | ||
| Q3 24 | — | $0.16 | ||
| Q2 24 | — | $-0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $232.0M | $195.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $626.5M | $-98.0M |
| Total Assets | $974.7M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $195.0M | ||
| Q3 25 | — | $445.0M | ||
| Q2 25 | $232.0M | $510.0M | ||
| Q1 25 | — | $373.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | $109.8M | — |
| Q4 25 | — | $-98.0M | ||
| Q3 25 | — | $-207.0M | ||
| Q2 25 | $626.5M | $-257.0M | ||
| Q1 25 | — | $-285.0M | ||
| Q3 24 | — | $-310.0M | ||
| Q2 24 | $475.4M | $-281.0M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $974.7M | $1.5B | ||
| Q1 25 | — | $1.4B | ||
| Q3 24 | — | — | ||
| Q2 24 | $796.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $47.1M | $-221.0M |
| Free Cash FlowOCF − Capex | — | $-245.0M |
| FCF MarginFCF / Revenue | — | -68.6% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | 0.69× | -2.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-221.0M | ||
| Q3 25 | — | $-39.0M | ||
| Q2 25 | $47.1M | $158.0M | ||
| Q1 25 | — | $75.0M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | $70.1M | $88.0M |
| Q4 25 | — | $-245.0M | ||
| Q3 25 | — | $-59.0M | ||
| Q2 25 | — | $141.0M | ||
| Q1 25 | — | $70.0M | ||
| Q3 24 | — | $-5.0M | ||
| Q2 24 | — | $84.0M |
| Q4 25 | — | -68.6% | ||
| Q3 25 | — | -18.8% | ||
| Q2 25 | — | 46.7% | ||
| Q1 25 | — | 26.3% | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | — | 28.1% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 5.6% | ||
| Q1 25 | — | 1.9% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 1.3% |
| Q4 25 | — | -2.15× | ||
| Q3 25 | — | -0.93× | ||
| Q2 25 | 0.69× | 8.78× | ||
| Q1 25 | — | 1.60× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | 1.33× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAMT
Segment breakdown not available.
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
